Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Lux Research
Lux Research
Activities:
Media
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Transdermal patch delivery technologies will create new blockbuster drugs, says report
Drug delivery via transdermal patches will lead to US$6bn in new annual sales within the next 10 years
Research & Development
China invests billions to catch up with western pharma
China has spent US$160bn on biomedicine, and is poised to surpass Japan to become the second-largest spender on R&D
Media
Fourth-generation biologics set to grow US$120bn market, finds report
Several factors place antibodies at the front of the biologicals wave, says consultancy Lux Research
Media
Big pharma missing out on nanotech opportunities, says report
Pharmaceutical companies have been accused of risking missing the opportunities offered by the latest technological zeitgeist, that of nanotechnology
Subscribe now